Abivax S.A.
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
ABVX | US
Overview
Corporate Details
- ISIN(s):
- US00370M1036
- LEI:
- Country:
- United States of America
- Address:
- 7 BD HAUSSMANN, 0 PARIS
- Website:
- https://www.abivax.com/
- Sector:
- Manufacturing
Description
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's core strategy revolves around modulating the immune response through microRNA (miRNA). Its lead drug candidate, obefazimod, is an investigational, orally administered small molecule with a novel mechanism of action. Obefazimod is designed to enhance the expression of miR-124, a key microRNA that regulates the inflammatory response. The primary development goal is the commercialization of obefazimod for the treatment of ulcerative colitis, with clinical programs also underway for Crohn's disease. The company is exploring obefazimod for other inflammatory indications and is investigating follow-on compounds from its proprietary chemical library.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abivax S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abivax S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abivax S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
